Unraveling the multifaceted role of EpCAM in colorectal cancer: an integrated review of its function and interplay with non-coding RNAs
- 27 December 2023
- journal article
- review article
- Published by Springer Nature in Medical Oncology
- Vol. 41 (1) , 1-12
Abstract
The epithelial cell adhesion molecule (EpCAM) is a critical glycoprotein involved in cell cycle progression, proliferation, differentiation, migration, and immune evasion. Its role as a target for bispecific antibodies has shown promise in annihilating cancer cells. EpCAM's potential as a biomarker for tumor-initiating cells, characterized by self-renewal and tumorigenic capabilities, underscores its value in early cancer detection, immunotherapy, and targeted drug delivery. While EpCAM monotherapies have been met with limited success, bispecific antibodies targeting both EpCAM and other proteins have exhibited encouraging results in colorectal cancer (CRC) research. The integration of EpCAM-directed nanotechnology in drug delivery systems has emerged as a pivotal innovation in CRC treatment. Moreover, developing chimeric antigen receptor (CAR) T-cell and CAR natural killer (NK) cell therapies opens promising therapeutic avenues for EpCAM-positive CRC patients. Although preliminary, this review sets the stage for future advances. Additionally, this study advances our understanding of the role of non-coding RNAs in CRC, which may be pivotal in gene regulation and could provide insights into the molecular underpinning. The findings suggest that lncRNA, miRNA, and circRNA could serve as novel therapeutic targets or biomarkers, further enriching the landscape of CRC diagnostics and therapeutics.Keywords
This publication has 56 references indexed in Scilit:
- Characterization of metastatic breast cancer patients with nondetectable circulating tumor cellsInternational Journal of Cancer, 2010
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trialInternational Journal of Cancer, 2010
- An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancerAnnals of Oncology, 2010
- Extracellularly Activated Nanocarriers: A New Paradigm of Tumor Targeted Drug DeliveryMolecular Pharmaceutics, 2009
- Isolation of rare circulating tumour cells in cancer patients by microchip technologyNature, 2007
- Loss of membranous Ep-CAM in budding colorectal carcinoma cellsLaboratory Investigation, 2007
- Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancerGynecologic Oncology, 2006
- The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferationOncogene, 2004
- Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinomaThe Lancet, 1994
- Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule.Journal of Cell Biology, 1994